Ameratunga Rohan, Steele Richard, Jordan Anthony, Preece Kahn, Barker Russell, Brewerton Maia, Lindsay Karen, Sinclair Jan, Storey Peter, Woon See-Tarn
Departments of Clinical Immunology, Virology and immunology, Auckland City Hospital, Auckland, New Zealand.
N Z Med J. 2016 Jun 10;129(1436):75-90.
Primary immune deficiency disorders (PIDs) are rare conditions for which effective treatment is available. It is critical these patients are identified at an early stage to prevent unnecessary morbidity and mortality. Treatment of these disorders is expensive and expert evaluation and ongoing management by a clinical immunologist is essential. Until recently there has been a major shortage of clinical immunologists in New Zealand. While the numbers of trained immunologists have increased in recent years, most are located in Auckland. The majority of symptomatic PID patients require life-long immunoglobulin replacement. Currently there is a shortage of subcutaneous and intravenous immunoglobulin (SCIG/IVIG) in New Zealand. A recent audit by the New Zealand Blood Service (NZBS) showed that compliance with indications for SCIG/IVIG treatment was poor in District Health Boards (DHBs) without an immunology service. The NZBS audit has shown that approximately 20% of annual prescriptions for SCIG/IVIG, costing $6M, do not comply with UK or Australian guidelines. Inappropriate use may have contributed to the present shortage of SCIG/IVIG necessitating importation of the product. This is likely to have resulted in a major unnecessary financial burden to each DHB. Here we present the case for a national service responsible for the tertiary care of PID patients and oversight for immunoglobulin use for primary and non-haematological secondary immunodeficiencies. We propose that other PIDs, including hereditary angioedema, are integrated into a national PID service. Ancillary services, including the customised genetic testing service, and research are also an essential component of an integrated national PID service and are described in this review. As we show here, a hub-and-spoke model for a national service for PIDs would result in major cost savings, as well as improved patient care. It would also allow seamless transition from paediatric to adult services.
原发性免疫缺陷病(PIDs)是一类罕见疾病,但有有效的治疗方法。尽早识别这些患者对于预防不必要的发病和死亡至关重要。这些疾病的治疗费用高昂,临床免疫学家的专业评估和持续管理必不可少。直到最近,新西兰临床免疫学家严重短缺。尽管近年来经过培训的免疫学家数量有所增加,但大多数都在奥克兰。大多数有症状的PID患者需要终身进行免疫球蛋白替代治疗。目前新西兰皮下和静脉注射免疫球蛋白(SCIG/IVIG)短缺。新西兰血液服务局(NZBS)最近的一项审计显示,在没有免疫学服务的地区卫生委员会(DHBs)中,SCIG/IVIG治疗指征的合规性较差。NZBS的审计表明,每年约20%的SCIG/IVIG处方(花费600万美元)不符合英国或澳大利亚的指南。不当使用可能导致了目前SCIG/IVIG的短缺,从而需要进口该产品。这可能给每个DHB带来了重大的不必要财务负担。在此,我们提出设立一项国家服务,负责PID患者的三级护理以及对原发性和非血液学继发性免疫缺陷患者免疫球蛋白使用的监督。我们建议将其他PID,包括遗传性血管性水肿,纳入国家PID服务。辅助服务,包括定制的基因检测服务和研究,也是综合国家PID服务的重要组成部分,本综述对此进行了描述。正如我们在此所示,PID国家服务的中心辐射模式将带来大幅成本节约,同时改善患者护理。它还将实现从儿科服务到成人服务的无缝过渡。